Caroline Bret

Montpellier, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

Journal: Translational oncology

Published: May 25, 2026

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

Journal: American journal of hematology

Published: April 06, 2026

MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.

MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.

Journal: Cell reports

Published: December 19, 2025

Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL.

Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL.

Journal: Blood

Published: August 22, 2025

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.

CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.

Journal: Oncoimmunology

Published: July 20, 2025

Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma.

Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma.

Journal: EMBO molecular medicine

Published: April 22, 2025

Infectious Complications in Children, Adolescents, and Young Adults Treated for Acute Leukemia and Lymphoblastic Lymphoma: A Single-Center Experience.

Infectious Complications in Children, Adolescents, and Young Adults Treated for Acute Leukemia and Lymphoblastic Lymphoma: A Single-Center Experience.

Journal: Journal of pediatric hematology/oncology

Published: April 16, 2025

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma.

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High-Risk Diffuse Large B Cell Lymphoma.

Journal: Hematological oncology

Published: April 14, 2025

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.

Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.

Journal: Theranostics

Published: August 02, 2024

BHLHE41, a transcriptional repressor involved in physiological processes and tumor development.

BHLHE41, a transcriptional repressor involved in physiological processes and tumor development.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: July 11, 2024

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.

Journal: Blood neoplasia

Published: June 24, 2024

Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms (MPO-MDS-Valid): protocol for a multicentre diagnostic accuracy study.

Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms (MPO-MDS-Valid): protocol for a multicentre diagnostic accuracy study.

Journal: BMJ open

Published: June 18, 2024

Showing 1-12 of 37

Last Updated: 09/26/2026